Bigfoot Biomedical is a new kind of medical device company developing technologies to significantly reduce the cognitive, emotional, and financial burden of insulin-requiring diabetes. With an intense focus on ease of use, Bigfoot will optimize the dosing and delivery of insulin through an integrated medical device ecosystem powered by machine learning and enhanced by secure, user-friendly consumer technologies, fundamentally changing the paradigm of care. The company’s pioneering smartphone-enabled systems include both automated infusion pump and connected insulin pen options for consumers and will be delivered via a first-of-its-kind monthly subscription service model. Bigfoot will be the first company to deliver a monthly subscription-based service leveraging a smart, connected insulin dosing platform to meet the needs of a diverse population with insulin-requiring diabetes. Bigfoot’s investigational system is comprised of best-in-class proprietary and licensed components holistically and securely integrated, leveraging intuitive design, machine learning, and a mobile app running on an off-the-shelf smartphone, all designed to keep glucose levels